Navigation Links
Lead Therapeutic Candidate for Treatment of Pain from Adynxx, AYX1, Well-Tolerated in Phase 1 Clinical Study
Date:9/5/2012

SAN FRANCISCO, Sept. 5, 2012 /PRNewswire/ -- Adynxx, a clinical-stage pharmaceutical company developing a first-in-class platform of therapeutics to address pain at its molecular roots, announced today that its lead investigational drug candidate for the prevention of acute and chronic post-operative pain, AYX1, was well-tolerated in a Phase 1 clinical study.

The 30-subject, dose-escalating study evaluated AYX1 in five cohorts of healthy volunteers. AYX1 was well-tolerated at all dose levels, with no serious adverse events reported and no subjects withdrawing from the study.  This positions Adynxx to move AYX1 into a proof-of-concept Phase 2 clinical study later this year. That study will assess the ability of a single administration of AYX1 at the time of surgery to reduce acute pain immediately after surgery, prevent the transition to persistent post-surgical pain, and consequently improve functional recovery. Long-term efficacy of AYX1 after a single administration has been demonstrated in a variety of preclinical pain and functional assessment models.

"We recognize that patients and physicians need new treatment options for post-surgical pain that address its root causes," said Donald Manning, M.D., Ph.D. chief medical officer of Adynxx. "With AYX1, we are aiming to treat post-operative pain as a disease that can be effectively prevented with a single, safe administration at the time of surgery.  Given the urgent need for new pain therapies, we look forward to continuing the advancement of AYX1 and other therapeutics in our pipeline at an aggressive pace."

Added Julien Mamet, Ph.D., founder and chief scientific officer of Adynxx, "We started this company to specifically advance therapeutics that can transform the treatment of pain for patients and physicians. AYX1 has a unique mechanism of action that simultaneously neutralizes multiple molecular mechanisms responsible for the maintenance of pain following surgery. We believe AYX1 will provide a valuable new treatment option to reduce the severity and duration of post-surgical pain suffered by patients."   

In addition to AYX1, Adynxx is advancing a pipeline of therapeutics for treatment of other indications, including intractable neuropathic pain and inflammatory pain syndromes such as chronic lower back pain.

About Adynxx

Adynxx, located in San Francisco, California, is a clinical stage pharmaceutical company developing a transformative technology platform addressing pain at its molecular roots - preventing the development of pain following surgery or trauma and resolving established chronic pain syndromes.  Adynxx's unique approach is to transform pain management by approaching pain as a disease rather than a symptom. 

Adynxx's lead compound, AYX1, is an investigational drug designed to prevent acute post-surgical pain and the transition to persistent or chronic pain with a single administration at the time of surgery.  Adynxx has completed a Phase 1 clinical trial of AYX1 and plans to initiate a Phase 2 study of AYX1 in Q4 2012.  AYX2, intended to resolve multiple forms of chronic lower back pain, is currently in pre-clinical development along with AYX3, intended to target a range of intractable neuropathic and inflammatory pain syndromes. For more information, visit www.adynxx.com

Media Contact:

David Schull or Ian Stone
Russo Partners
(858) 717-2310
(619) 308-654
david.schull@russopartnersllc.com
ian.stone@russopartnersllc.com

 


'/>"/>
SOURCE Adynxx
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
2. Novelos Therapeutics to Present at Rodman & Renshaw 14th Annual Healthcare Conference on September 11
3. Echo Therapeutics to Present at the Rodman & Renshaw Annual Global Investment Conference
4. ImmusanT Initiates Clinical Trials of Nexvax2 Therapeutic Vaccine for Celiac Disease
5. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
6. Cell Therapeutics, Inc. (CTI) Appoints Former Managing Director, Head of West Coast Biotechnology for Oppenheimer/CIBC Matthew J. Plunkett Executive Vice President, Corporate Development
7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
8. Global Markets for Animal Therapeutics and Diagnostics
9. Human Vaccines & Immunotherapeutics Special Focus Highlights a Paradigm Shift in Cancer Vaccine Development
10. Aethlon Medical Discusses Therapeutic Device Strategies to Address Cancer, Hepatitis-C and Sepsis with the Wall Street Transcript
11. Prime Therapeutics named exclusive pharmacy benefit manager for HR Policy Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... -- Express Scripts (NASDAQ: ESRX ) was recognized today by ... the Health Care: Pharmacy and Other Services category. "Express ... Admired Companies," said Tim Wentworth , CEO and President, Express ... our 26,000 employees to make medicine more affordable and accessible for ... ...
(Date:2/16/2017)... and SCOTTSDALE, Ariz. , Feb. 16, ... Health Information Exchange (HIE), announced today it is partnering with ... HealthInfoNet,s HIE contains 98% of all Maine ... Maine hospitals and over 500 ambulatory care ... Directors, HealthInfoNet plans to deploy Orion Health,s Amadeus , ...
(Date:2/16/2017)... and TEL AVIV, Israel ... a global interventional cardiology device company, today announced ... M.D., founder and past Chairman and Chief Executive ... created position of Executive Chairman of Medinol US ... Medinol,s global management in the areas of business ...
Breaking Medicine Technology:
(Date:2/16/2017)... ... February 17, 2017 , ... Harsha Chigurupati knows the meaning ... development and clinical trials, the founder of Chigurupati Technologies has invented India’s first ... approved ingredients that when infused into alcohol, protect the consumer’s liver and DNA, ...
(Date:2/16/2017)... , ... February 17, 2017 , ... Teaching nursing care ... program, now in development. ACE.P (pediatrics) is being created with the support of the ... of Vulnerable Populations , ACE.P will address what has been identified as a critical ...
(Date:2/16/2017)... Kisco, New York (PRWEB) , ... February 16, ... ... Hospital’s (NWH) nursing professionalism, teamwork and superiority in patient care, NWH has ... of the Commission on Magnet on Tuesday, January 31, 2017. The American Nurses ...
(Date:2/16/2017)... ... February 16, 2017 , ... ... doegedevelopment.com/contact/ , doegedevelopment.com , David A Doege is excited to announce ... commercial tenant improvements, ground up new builds, design build, and site improvements. , ...
(Date:2/16/2017)... ... February 16, 2017 , ... A February 6 article ... freezing or CoolSculpting, noting that some 425,000 procedures were performed with the new technology ... clinic is, in fact, seeing a great deal of interest from area patients who ...
Breaking Medicine News(10 mins):